Skip to content
SK Biopharmaceuticals
-
SK Biopharmaceuticals adds Parkinson’s disease drug to pipeline in US$315M deal
Under the agreement, 1ST Biotherapeutics will receive US$1.8 million upfront and an additional US$1.8 million payment in the near term.
-
Biohaven collaborates with SK Pharmaceuticals on Opakalim to treat focal epilepsy
Biohaven is currently evaluating the therapy in the Phase II/III RISE3 study, with results expected in the second half of 2026.
-
SK Biopharmaceuticals expands oncology pipeline with US radiopharmaceutical deal.
WT-7695, a preclinical radiopharmaceutical targeting carbonic anhydrase IX (CA9), was developed in collaboration with the University of Wisconsin-Madison, and SK now holds exclusive worldwide rights to develop, manufacture, and market the drug.